Intranasal GSH (Phase IIb): Randomized, double-blind, placebo-controlled study (n=45) tested intranasal reduced GSH 100 or 200 mg three times daily for 12 weeks
An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice
[5] [6] Early-phase clinical trials including a Phase 2 trial published in the New England Journal of Medicine (2023) have reported significant reductions in body weight and improvements in metabolic markers, though this evidence remains preliminary and is not sufficient to establish a clinical dosing or reconstitution standard
If I had questions I would call and get answers immediately
As a content creator, presentation matters, and the packaging looked professional
Medicines in the GLP-1 receptor agonist class, including semaglutide, have been associated with pancreatitis and gallbladder problems